KRAS and familial pancreatic carcinoma: It has demonstrated promising clinical activity in phase I/II trials across multiple malignancies, including non-small cell lung cancer, advanced melanoma, hormone receptor-positive breast cancer, and KRAS-mutant colorectal and pancreatic cancers (80–83).